Phaseline

Companies › Guangdong Raynovent Biotech

Guangdong Raynovent Biotech: clinical trials, targets and expected readouts

3 active drug programs in 7 registered trials: 3 Phase 3, 3 Phase 2, 1 Phase 1; Infectious disease, Metabolic and endocrine, Gastroenterology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
RAY1225
Unclear - mechanism not specified in registry text
–Phase 3Obesity; T2DM (Type 2 Diabetes Mellitus)–
ZSP1273
Neuraminidase inhibitor
–Phase 3Influenza A; Influenza a–
ZSP1601
FGF21 receptor agonist
–Phase 2Nonalcoholic Steatohepatitis (NASH)Dec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06254274RAY1225Phase 2T2DM (Type 2 Diabetes Mellitus)Metabolic and endocrineJul 2025
NCT06254261RAY1225Phase 2ObesityMetabolic and endocrineDec 2025
NCT07229820ZSP1273Phase 3Influenza AInfectious diseaseDec 2025
NCT07362030RAY1225Phase 1ObesityMetabolic and endocrineDec 2025
NCT07229807ZSP1273Phase 3Influenza aInfectious diseaseJan 2026
NCT06893016RAY1225Phase 3ObesityMetabolic and endocrineJun 2026
NCT05692492ZSP1601Phase 2Nonalcoholic Steatohepatitis (NASH)GastroenterologyDec 2026

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Madrigal Pharmaceuticals Rivus Pharmaceuticals Insud Pharma Visirna Therapeutics HK Eccogene

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.